Zenas BioPharma, Inc. Common Stock (ZBIO) Stock
Key stats
- Market cap
- $1.95B
- Price / Earnings ratio
- -3.6x
- EPS (TTM)
- -$10.05
- Volume
- Loading
- 52-week high
- $44.60
- 52-week low
- $13.50
Source: third-party data provider, as of November 13, 2026
Compare with ZBIO
Recent news

Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision Nears
Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision Nears
ZBIO

Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's What You Should Know
Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's What You Should Know
ZBIO

Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.
Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.
ZBIO

ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch
ZBIO
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 53.36
- MACD 12/26/9
- 0.06
- EMA 9 of MACD
- -0.14
- MACD histogram
- 0.20
- SMA 50
- $28.79
- Price below SMA 50
- EMA 50
- $28.31
- Price above EMA 50
- SMA 200
- $25.28
- Price above SMA 200
- EMA 200
- $27.08
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision Nears
Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision Nears
ZBIO

Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's What You Should Know
Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's What You Should Know
ZBIO

Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.
Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.
ZBIO

ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch
ZBIO

ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study
ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study
ZBIO

Zenas BioPharma, A Top 1% Stock, Quadrupled In 2025. Why It Just Collapsed.
Zenas BioPharma, A Top 1% Stock, Quadrupled In 2025. Why It Just Collapsed.
ZBIO

Zenas BioPharma's immune disorder drug meets main goal in late-stage trial
Zenas BioPharma's immune disorder drug meets main goal in late-stage trial
ZBIO
News tone: automated (AI) classification of the article's content, not a price prediction.
About Zenas BioPharma, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Leon Oliver Moulder Jr., M.B.A. | Founder, CEO & Chairman | 1957 |
| Mr. Joseph L. Farmer | COO & President | 1972 |
| Ms. Jennifer A. Fox | Chief Business Officer & CFO | 1972 |
| Dr. Lisa von Moltke M.D. | Head of Research & Development and Chief Medical Officer | 1959 |
| Dr. Heinrich Schlieker Ph.D. | Chief Technical Officer | — |
| Dr. Haley Laken Ph.D. | Chief Scientific Officer | — |
| Ms. Caroline Chevalier | Chief Administrative Officer | — |
| Mr. Jeffrey Held | Chief Legal Officer | 1969 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 53.36
- MACD 12/26/9
- 0.06
- EMA 9 of MACD
- -0.14
- MACD histogram
- 0.20
- SMA 50
- $28.79
- Price below SMA 50
- EMA 50
- $28.31
- Price above EMA 50
- SMA 200
- $25.28
- Price above SMA 200
- EMA 200
- $27.08
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $32.00
- Average
- $44.80
- High
- $55.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -6.8 | +24.6 | -43.8 | -26.9 | ||||||||
| 2025 | -11.0 | -5.4 | +19.0 | +52.4 | -17.6 | -3.7 | +71.9 | +3.8 | +26.7 | +41.3 | +23.9 | -2.1 |
| 2026 | -46.8 | +45.2 | -23.5 | -5.1 | -5.0 | +39.7 | +12.3 | +3.8 | -15.7 | +1.6 | +3.9 |



